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Abstract
Multiple organ dysfunction induced by sepsis often involves kidney injury. Extracellular his-
tones released in response to damage-associated molecular patterns are known to facilitate
sepsis-induced organ dysfunction. Recombinant human soluble thrombomodulin (rhTM)
and its lectin-like domain (D1) exert anti-inflammatory effects and neutralize damage-asso-
ciated molecular patterns. However, the effects of rhTM and D1 on extracellular histone H3
levels and kidney injury remain poorly understood. Our purpose was to investigate the asso-
ciation between extracellular histone H3 levels and kidney injury, and to clarify the effects of
rhTM and D1 on extracellular histone H3 levels, kidney injury, and survival in sepsis-induced
rats. Rats in whom sepsis was induced via cecal ligation and puncture were used in this
study. Histone H3 levels, histopathology of the kidneys, and the survival rate of rats at 24 h
after cecal ligation and puncture were investigated. Histone H3 levels increased over time
following cecal ligation and puncture. Histopathological analyses indicated that the distribu-
tion of degeneration foci among tubular epithelial cells of the kidney and levels of histone H3
increased simultaneously. Administration of rhTM and D1 significantly reduced histone H3
levels compared with that in the vehicle-treated group and improved kidney injury. The sur-
vival rates of rats in rhTM- and D1-treated groups were significantly higher than that in the
vehicle-treated group. The results of this study indicated that rhTM and its D1 similarly
reduce elevated histone H3 levels, thereby reducing acute kidney injury. Our findings also
proposed that rhTM and D1 show potential as new treatment strategies for sepsis combined
with acute kidney injury.
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Introduction
Sepsis is a life-threatening healthcare issue caused by infection, and associated with a high risk
of mortality. In sepsis, inflammatory response occurs following infection and sometimes con-
tributes to the development of various organ dysfunctions. Kidney injury is one of the most
common organ dysfunctions induced by sepsis. Once a sepsis patient develops complications
of acute kidney injury (AKI), mortality is reportedly increased [1–3].
In recent years, extracellular histones have been attracting attention as mediators of death
from sepsis [4]. Extracellular histones are known as damage-associated molecular patterns
(DAMPs) and are released when cellular injury occurs, resulting in induction of neutrophil
migration, platelet aggregation, and endothelial cell damage [5, 6]. DAMPs are likely to trigger
the activation of serious inflammation [7] and result in severe tissue injury [8–12]. Suppression
of the production of inflammatory mediators such as cytokines and DAMPs could thus con-
tribute to the improvement of clinical outcomes in critically ill patients.
Thrombomodulin (TM) is a thrombin-binding anticoagulant cofactor that is expressed on
the surface of endothelial cells and plays an important role in the regulation of intravascular
coagulation [13]. The structure of TM consists of five domains: the N-terminal lectin-like
domain (D1), a domain with six epidermal growth factor (EGF)-like structures (D2), a serine
and threonine-rich domain (D3), a transmembrane domain (D4), and a short cytoplasmic
domain (D5) [14]. Recent studies have shown that D1 has anti-inflammatory effects, inhibits
the production of inflammatory cytokines, and also binds to high-mobility group box-1
(HMGB1), which is a known damage-associated molecular pattern (DAMP) [15, 16]. How-
ever, whether administration of TM could suppress extracellular histone H3 levels and
improve organ injury remains unclear. In addition, whether administration of D1 has the
same effects on histone H3 levels and protective effects against kidney injury remains to be
clarified. We hypothesized that administration of TM and D1 would improve kidney injury
and survival rate in sepsis-induced rats by inhibiting extracellular histone H3 release. Recom-
binant human soluble TM (rhTM) is homologous with the extracellular domains of TM and is
used as an anticoagulant in treatment of disseminated intravascular coagulation in Japan. The
purposes of this study were: 1) to investigate the relationship between extracellular histone H3
levels and kidney injury; and 2) to clarify whether rhTM and D1 could affect extracellular his-
tone H3 levels, kidney injury, and survival rate of sepsis-induced rats.
Materials and methods
Cecal ligation and puncture (CLP)-induced sepsis model in rats
Male Wistar rats were obtained from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan). The rats
weighing 250–300 g were used after an acclimation period of at least 1 week before experimen-
tation. Rats were maintained in a 12/12 h light/dark cycle to minimize noises, vibrations and
odors. The animals were kept in temperatures of 22–24˚C with 40–50% humidity. Food and
clean water were freely accessible at all times. Therefore, not all animal welfare considerations
taken were necessary, including efforts to minimize suffering and distress, use of analgesics or
anesthetics, or special housing conditions. To create an in vivo sepsis-induced model, we per-
formed CLP procedures as follows. Rats were anesthetized with isoflurane, and a 1.5-cm inci-
sion was made along the abdominal midline. Ligation was performed at a distance of 1–2 cm
from the blind-ending cecum, avoiding the mesenteric vessels of the cecum. The distal cecum
was then punctured once with an 18-G needle, and a small amount of feces was gently
squeezed out. The cecum was returned to the abdominal cavity, and layers of the abdominal
incision were sequentially sutured. The sham rats were anesthetized and underwent the same
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procedure without CLP. After the surgical procedure, rats were subcutaneously injected with
10 mL/kg of saline. Rats were deprived of food and free access to water after CLP.
rhTM and D1 were used for experimental studies at the indicated dose, which was provided
by Asahi Kasei Pharma (Tokyo, Japan). The molecular weights of rhTM and D1 are 52,171 Da
and 20,191 Da, respectively. The dose of D1 in this study was thus calculated as 0.36 of the
rhTM dose by conversion according to relative molecular weights for equivalent titration.
Blood samples were collected by cardiac puncture in EDTA-containing blood collection
tubes at each time point under general anesthesia and centrifuged at 1500×g for 10 min. The
supernatant after centrifugation was collected and stored at -80˚C until further analyses.
All experimental protocols described in the present study were approved by the Institu-
tional Animal Care and Use Committee of Sapporo Medical University (Permit No. 19–023).
The staff who conducted this experiment had taken a special seminar and training in animal
care or handling that were approved by the ethics committee of our university. All efforts were
made to minimize animal suffering. In the present study, as the humane end point for rats, a
state of respiratory urgency, continuous laying, or convulsion was judged as indicative of a
moribund state and treated with euthanasia. Once an animal reached endpoint criteria, they
were euthanized immediately and counted as an animal death. Euthanasia was performed by
deep anesthesia with isoflurane, causing irreversible cardiac or respiratory arrest. Animal
health and behavior were observed carefully every 30 minutes after the CLP procedure. Addi-
tionally, animal welfare was checked every 4 h until 24 h after the procedure.
In the first line of experiments, we examined the levels of circulating histone H3 and effec-
tive concentrations of rhTM. The sample size was determined to be at least 5 rats per group via
power analysis based on a previous study [17]. We used new rats every 4 h from 0 to 24 h, with
5 rats in each group: sham, vehicle, low-, middle-, and high-dose groups (Figs 1 and 2). In the
second line of experiments, we used 6 animals in each group to verify the effects of both rhTM
and D1 on histone H3 levels after CLP (Figs 3–7). In the third line of experiments, we used 10
animals in each group to confirm the pharmacological effects of these proteins (rhTM and D1)
on animal models to check animal welfare (Fig 8). A total of 124 rats were used in this study
and all of them were euthanized after meeting the endpoint criteria within 24 h. Data from all
rats that underwent experimentation were included in this study, with none excluded.
Fig 1. Circulating histone H3 level after CLP procedure. Circulating histone H3 level elevated over time. n = 5 per
group. † P� 0.01 vs. 0 h.
https://doi.org/10.1371/journal.pone.0228093.g001
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Determination of histone H3 levels after CLP
We investigated changes in circulating histone H3 levels after CLP. Blood samples were col-
lected from rats under general anesthesia. We observed the rats every 4 h until 24 h after
the end of the CLP procedure. Thus, the duration of the experiment was set at 24 h. We
determined the timing of elevations in histone H3 levels. Commercial enzyme-linked
Fig 2. Effectiveness of rhTM for reducing histone levels. Circulating histone H3 levels were significantly lower with
administration of middle- or high-dose (3 mg/kg or 6 mg/kg) rhTM compared to control group administered vehicle.
n = 5 per group. † P� 0.01 vs. vehicle.
https://doi.org/10.1371/journal.pone.0228093.g002
Fig 3. Effect of lectin-like domain 1 (D1) of rhTM on reduction of histone H3 levels in sepsis-induced rats.
Administration of rhTM and D1 significantly decreased circulating histone H3 levels. n = 6 per group. ‡ P� 0.001 vs.
vehicle.
https://doi.org/10.1371/journal.pone.0228093.g003
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immunosorbent assay kits were used for measurement of histone H3 levels (Shino-Test, Kana-
zawa, Japan) according to the instructions from the manufacturer.
Administration of rhTM after CLP or optimal dose of rhTM for affecting
histone H3 levels after CLP
We administered several doses of rhTM after CLP as a bolus injection into the tail vein to
determine the optimal dose of rhTM for affecting histone H3 levels. rhTM was administered
through the tail vein immediately after the CLP procedure. We set four groups: a control
group that received 2 mL of 0.9% saline as a vehicle; and low-, middle-, and high-dose groups
that received rhTM at 1 mg/kg, 3 mg/kg, and 6 mg/kg, respectively. Blood samples were
obtained at the time point of significant increases in histone H3 levels after the CLP procedures
in each group and histone H3 levels were compared between these four groups.
Administration of D1 after CLP
To evaluate the efficacy of D1 on histone H3 levels, 0.9% saline as a vehicle and a calculated
dose of D1 based on the optimal dose of rhTM were administered as a bolus injection into the
tail vein of rats after CLP. Blood samples were collected from rats under general anesthesia at
the time point of a significant increase in histone H3 levels after CLP. Histone H3 levels were
then determined and compared between vehicle- and D1-treated groups.
Determination of serum creatinine level
We evaluated serum creatinine level using blood samples obtained from the following groups:
sham, vehicle, rhTM, and D1. Serum creatinine concentrations in plasma were measured
using detection kits (Arbor Assays, Cat. #KB02-H1) according to the manufacturer’s
instructions.
Fig 4. Serum creatinine level in rats after CLP procedure. Administration of rhTM and D1 improved serum
creatinine levels. n = 6 per group. ‡ P� 0.001 vs. vehicle.
https://doi.org/10.1371/journal.pone.0228093.g004
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Histopathologic analysis of kidney
Kidney tissue specimens were obtained after euthanasia by deep anesthesia and were sub-
merged in 10% formaldehyde neutral buffer solution. Fixed tissues were embedded in paraffin,
cut at intervals of 3 μm, and stained with hematoxylin and eosin (HE). The number and size of
injured areas in the whole kidney were determined.
Fig 5. Histopathologic examination of kidney stained with HE. A) Histologic findings in rat kidney. Renal tissue was obtained 16
h after CLP and stained with HE. Arrowheads indicate degenerated areas. Representative images are shown at a magnification of
×200. B) Quantification of kidney degeneration in the four groups is shown (number of injured areas). n = 6 per group. C)
Quantification of kidney degeneration in the four groups (size of degenerated areas). n = 6 per group. † P� 0.01 vs. vehicle. ‡
P� 0.001 vs. vehicle. Scale bars = 200 μm.
https://doi.org/10.1371/journal.pone.0228093.g005
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Formalin-fixed hemisected kidneys were embedded in paraffin and stained with periodic
acid-Schiff (PAS). Histological analysis of kidney tubular cell damage was performed using the
following scoring assessment: 0, no damage; 1, mild (PAS-positive brush border that is lost in
<1/3 of the injured area); 2, moderate (<2/3); 3, severe (complete loss or�2/3).
Fig 6. Histopathologiccal examination of kidney stained with PAS. A) Histologic findings in rat kidney. Renal tissue
was obtained 16 h after CLP and stained with PAS. Arrowheads indicate degenerated areas and arrows indicate the
PAS-positive brush border. Representative images are shown at a magnification of ×400. B) The score of the PAS-
positive brush border in the four groups is shown (score of PAS = positive brush border). n = 6 per group. ‡ P� 0.001
vs. vehicle. Scale bars = 100 μm.
https://doi.org/10.1371/journal.pone.0228093.g006
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Immunohistochemical staining of the kidney and quantification
Immunohistochemical staining for histone H3 was performed using rabbit polyclonal anti-
body (Lot. 001; Shino-Test). After antigen retrieval and blocking, sections were preincubated
with 10% normal goat serum for 20 min. Sections were incubated with a 1:500 dilution of the
primary antibody histone H3 for 15 min. Sections were then incubated with Bond™ Polymer
Refine Detection (Leica Biosystems, Newcastle-Upon-Tyne, UK). The chromogen was 3,3’-
diaminobenzidine (DAB), followed by counterstaining with hematoxylin. Staining intensity
was graded as: 0, negative; 1, weak; 2, moderate; or 3, strong. A grade of 2 or 3 was considered
positive for immunohistochemical staining, whereas a grade of 0 or 1 was considered negative.
We counted the positive cells in a randomly selected microscopic field at high magnification
(×400). Quantitative analysis of histone H3 expression was performed using histological
images that were digitally obtained using a light microscope in order to best reflect overall
immunostaining of the specimen on each slide. Camera control with constant setup conditions
Fig 7. Histopathologic examination of kidney with immunohistochemical staining for histone H3. A)
Immunohistochemical findings in rat kidney. Renal tissue was obtained 16 h after CLP and stained with antihistone H3
peptide polyclonal antibody. Representative images are shown at a magnification of ×200. B) Quantification of positive cells
for immunohistochemical staining in the four groups is shown. n = 6 per group. ‡ P� 0.001 vs. vehicle. Scale bars = 200 μm.
https://doi.org/10.1371/journal.pone.0228093.g007
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was maintained throughout the course of the study. Adobe Photoshop software (Adobe Sys-
tems, Mountain View, CA) was used to process acquired images. For quantification, positive
signals were selected using a constant threshold in each image at high magnification (×400).
All immunohistochemical specimens were evaluated by a board-certified pathologist (Depart-
ment of Pathology, Sapporo Medical University School of Medicine, Japan).
Survival analysis
To evaluate the effects of rhTM and D1 on survival rate after CLP, rats were divided into four
groups: a sham group of rats without CLP; a control group of rats administered vehicle after
CLP; an rhTM group of rats administered the optimal dose of rhTM after CLP; and a D1
group of rats administered D1 (0.36 of rhTM dose) after CLP. Survival of the rats was moni-
tored up to for 24 h. We analyzed and compared survival rates of rats between these four
groups.
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM). Statistical analysis
between groups was performed by Tukey’s multiple comparison test. Survival rate was ana-
lyzed by the Kaplan-Meier method using log-rank testing. Analyses were performed with
Graph Pad Prism version 6.0h software (GraphPad Software, San Diego, CA). The level of sig-
nificance was set at 0.05 for all analyses using two-tailed P values.
Results
Serial changes in extracellular histone H3 levels after CLP procedure
Circulating histone H3 level began to significantly increase at 16 h after CLP and continued to
increase up to 24 h (Fig 1). Based on this result for this timing, we decided to evaluate extracel-
lular histone H3 levels at 16 h after CLP in the following studies.
Fig 8. Survival curves in rats after CLP procedure. Rats were administered either: rhTM (green dotted line); D1 (red
dashed line); or saline as a vehicle (blue dashed dotted line). Sham rats are represented by the black solid line. n = 10
per group. � P< 0.05 vs. vehicle.
https://doi.org/10.1371/journal.pone.0228093.g008
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Effect of rhTM on histone H3 levels after CLP
Significant differences were found in circulating histone H3 levels at 16 h after CLP among the
four groups. Histone H3 levels in middle-dose (3 mg/kg) and high-dose (6 mg/kg) rhTM
groups were significantly lower than that in the control group administered vehicle only (Fig
2). Therefore, in the following experiment, we used rhTM dose at 3 mg/kg for evaluation of
rhTM efficacy on decreasing histone H3 level, improving survival rate and protective actions
on the kidney.
Effect of D1 on histone H3 levels after CLP
The administration dose of D1 was set at 1.09 mg/kg converted according to the molecular
weight of rhTM. Administration of D1 significantly reduced circulating histone H3 levels, sim-
ilar to rhTM (Fig 3). No significant difference in reduction of histone H3 levels was seen
between rhTM-treated and D1-treated groups.
Effect of rhTM and D1 on serum creatinine levels
Serum creatinine levels were significantly lower in rhTM- and D1-treated rats than in vehicle-
treated rats (Fig 4). No significant difference in serum creatinine level was seen between rhTM
and D1 groups.
rhTM and D1 improve histopathologic findings of the kidney
After CLP in rats, scattered degeneration foci were widely observed in tubular epithelial cells
and were widely distributed throughout the whole kidney in rats in the vehicle-treated group
(Fig 5A–5C). We observed that more severe degenerations were mainly observed in the tubu-
lar epithelium, suggesting peripheral circulatory insufficiency (Fig 5A). On the other hand, in
rats treated with rhTM and D1, tubular structure was maintained and degeneration was
observed in small areas. As a result of quantification, administration of rhTM and D1 signifi-
cantly decreased numbers and sizes of areas of degeneration in the kidney compared with
non-treated rats (Fig 5B and 5C). Also, we observed almost no or a small portion of the brush
border with PAS staining in the tubular lumen of kidneys in the vehicle group (Fig 6A). In
contrast, the structure of the brush border in the rhTM and D1 groups was maintained in
large areas, although there was partial injury to the tubular lumen (Fig 6A). The histological
scoring for the degree of kidney tubular damage in the rhTM and D1 groups was significantly
lower than the vehicle group (Fig 6B).
In rats from the sham group, immunostaining for histone H3 was mainly observed in the
cortical area. However, in rats from the vehicle-treated group, less immunostaining for histone
H3 was observed compared with the sham group (Fig 7A). Rats administered and D1 showed
more immunostaining for histone H3 compared with the vehicle-treated group. We per-
formed quantitative analysis of histone H3 expression in the cortical area for each group (Fig
7B). The number of positive cells in the non-treated group was significantly decreased com-
pared with the sham group. Administration of rhTM and D1 significantly increased the num-
ber of positive cells compared with the vehicle-treated group. Our data suggested that soluble
TM can rescue sepsis-induced renal tubular damage.
Survival rate
The survival rate at 24 h after CLP was 40% in the rhTM-treated group and 20% in the vehicle-
treated group. The difference in survival rate between the two groups was significant according
to Kaplan-Meier analysis (P = 0.048) (Fig 8). In the D1-treated group, the survival rate for 24 h
Recombinant human soluble thrombomodulin attenuates renal impairment by inhibition of histone
PLOS ONE | https://doi.org/10.1371/journal.pone.0228093 January 23, 2020 10 / 15
after the CLP procedure was 40%, compared with 20% in the vehicle-treated group. Kaplan-
Meier analysis revealed significant prolongation of survival in the D1-treated group compared
with the vehicle-treated group (P = 0.038) (Fig 8).
Discussion
The present study showed two important findings. First, circulating histone H3 levels elevated
over time and were associated with kidney injury diagnosed pathologically and from renal
function, and with high mortality in rats with intraabdominal infection-induced sepsis. Sec-
ond, we found that administration of rhTM and D1 dramatically reduced circulating histone
H3 levels, protected against kidney injury, and improved mortality in comparison with non-
treated rats with intraabdominal sepsis. From the present results, administration of rhTM
appears to be associated with renal protective effects via attenuation of histone H3 levels and
consequent improvement of survival rate in sepsis rats. The lectin-like domain of rhTM,
which does not show anticoagulant activity, is suggested to play a central role in anti-inflam-
matory activity. rhTM, and the D1 domain in particular, thus holds promise as a drug for the
treatment and prevention of septic AKI.
In this study, rhTM and D1 were administered at the time of CLP production. We found
that suppression of the increase in histone H3 levels is associated with improvement of kidney
injury. This shows the possibility that AKI is associated with increased serum histone H3 lev-
els. In the pathological examination of renal tissue, AKI was induced by CLP and a significant
decrease in intracellular histone protein levels was identified. However, whether the decrease
in intracellular histone H3 levels following AKI and the increase in serum histone H3 levels
are related remains unclear. In addition, it is not clear how circulating histone H3 causes
regional inflammation and cytotoxicity in the kidney. However, in general, leukocytes acti-
vated by inflammation are known to release histone H3, resulting in the elevation of histone
H3 levels in sepsis [18]. Moreover, histones, which are released into the extracellular space
through the process of cell death, cause kidney injury by direct cytotoxicity to renal tubular
epithelium and direct interaction with toll-like receptor (TLR)-2 (TLR2) and TLR4 [19].
Another study using the ischemia-reperfusion model in mice showed that extracellular his-
tones lead to multiple organ injury including kidney injury [20]. These histone-induced kid-
ney injuries are consistent with our data. In this study, there were no injuries to organs other
than the kidney in histological findings in rats with sepsis by CLP. In addition, histone H3 lev-
els were increased in sepsis-induced rats. From these two observations, we surmised that
increased histone H3 levels might be related to kidney injury. As for inflammatory markers,
we measured tumor necrosis factor-α (TNF-α) after the CLP procedure. TNF-α levels
increased earlier than the point when circulating histone H3 level increased, and the peaked
out (S1 Fig). Therefore, TNF-α did not increase at the time when circulating histone H3
increased and kidney injury occurred. In terms of kidney injury markers, we measured serum
creatinine levels as they are used as diagnostic criteria for acute kidney injury (Fig 4).
Conversely, Ito et al. [21] reported that depletion of leukocytes by anticancer drug-induced
bone marrow suppression resulted in inhibition of histone H3 production in a mouse model
of sepsis. Therefore, the increase in histone H3 levels in sepsis is thus highly possible to be
derived from leukocytes. Since this study showed pathological findings that CLP induced dis-
appearance of intracellular histone H3 in degenerated renal cells, damaged renal cells were
considered to release intracellular histone H3 into the extracellular space and this mechanism
is partially associated with increased serum histone H3 levels in sepsis rats.
Nuclear histone proteins have been reported to be released into the extracellular space and
act as major mediators of death in sepsis [4, 22]. In our sepsis model, extracellular histone H3
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levels increased significantly from 16 h after CLP. At that time, renal tissue showed extensive
degeneration and vacuolation with increased histone H3 levels. However, no findings of acute
tubular necrosis were identified. These findings show the early stage of AKI in pathological
evaluations.
Results of histological findings demonstrated microcirculatory disturbance, showing the
ischemic injury of kidney. Moreover, mortality rates of CLP-induced sepsis rats in the non-
treated group, in which histone H3 levels were high, were significantly higher than in the
rhTM and D1 treated groups. These results suggest that elevated histone H3 levels might be
associated with kidney injury and prognosis in intraabdominal sepsis-induced rats.
rhTM has been reported to bind to DAMPs, resulting in reduction of DAMPs levels
through inactivation by neutralization or decomposition. This elimination of released histone
H3 has been demonstrated to improve mortality in experimental investigations [23–25]. rhTM
comprises the following three structural regions: the lectin-like domain, the EGF-like domain,
and a serine-threonine-rich region. The lectin-like domain of the three structures has an anti-
inflammatory effect and a binding effect on HMGB1, a known DAMP [26]. Another study
showed that rhTM (particularly the lectin-like domain) protects the kidney from ischemia-
reperfusion injury via activated protein C (APC)-dependent and APC-independent mecha-
nisms [27]. On the other hand, endothelial dysfunction during ischemic injury caused by
inflammatory response results in microvascular congestion, leading to microcirculation
abnormalities [28, 29]. Endothelial cells play an important role in preventing intravascular
thrombus formation and maintain microcirculation [30]. However, the inhibitory effect of
rhTM and D1 on circulating histone H3 level remains poorly understood. We therefore
hypothesized that regulation of extracellular histone H3 by administration of rhTM and D1
would prevent sepsis-induced endothelial dysfunction, improve disturbances in microcircula-
tion, and result in improved renal injury and prognosis in a rat sepsis model.
In our experimental study, CLP induced a significant increase in circulating extracellular
histone H3 levels and induced AKI as evaluated pathologically and from serum creatinine lev-
els. Results of immunohistochemical staining of rat renal cells also demonstrated decreased
expression of histone H3. These data suggest that CLP-induced histone H3 elevation is associ-
ated with induction of AKI in rats.
Our results demonstrated that administration of rhTM and D1 inhibited CLP-induced his-
tone H3 elevation and mitigated CLP-induced AKI. Moreover, administration of both rhTM
and D1 improved prognosis of CLP-induced rats. Furthermore, results of immunohistochemi-
cal staining clearly demonstrated increased expression of histone H3 in rats that received
either rhTM or D1, preventing histone H3 from being released to the extracellular space.
These results suggest that rhTM and D1 might have the main effect of inhibiting the release of
histone H3. On the other hand, no significant differences were evident between the rhTM-
treated group and the D1-treated group in terms of the effects on inhibiting histone H3,
improving renal injury, and prognosis. The main domain of rhTM that exerts anti-inflamma-
tory action thus appears likely to be the lectin-like domain, D1.
The present study clearly demonstrated an association between increased histone H3 levels
and kidney injury, and indicated that administration of rhTM and D1 reduced histone H3 lev-
els and protected renal tissue. However, the following issues remain to be clarified in future
studies: 1) the mechanisms underlying suppression of histone H3 by rhTM and D1; and 2)
effects of rhTM and D1 on other organ injuries that were not examined in this study. Further
studies are thus needed in the future to clarify the mechanisms regulating histone H3 and pro-
tecting against organ injuries by rhTM and D1.
In the future, further studies are required to clarify the relationship between disappearance
of intracellular histone protein in renal tubular cells and increases in blood concentrations.
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Conclusions
CLP induced increases in extracellular histone levels, with this elevation peaking in the late
phase of sepsis followed by the peak in tumor necrosis factor (TNF)-α level. CLP also induced
AKI and this elevation of extracellular histone is thought to be related to CLP-induced AKI.
rhTM and its lectin-like domain D1 were found to similarly reduce these elevated histone H3
levels, thereby protecting against CLP-induced AKI and significantly improving the survival
rate of sepsis rats. Based on these facts, rhTM is considered to have anti-inflammatory activity
through the suppression of histone H3 levels, and thus may have renal protective activity. Fur-
thermore, since the D1 domain, which has no anticoagulant action among the domains of
rhTM, has the same effects on reducing histone H3 levels as rhTM did, these findings suggest
that the D1 domain may play a crucial role in anti-inflammatory activity among the domains
of rhTM. The results of our study suggest that rhTM and D1 domains may be useful drugs for
treating sepsis complicated by AKI. Our results also may provide a rationale for further clinical
studies of rhTM and its lectin-like domain as a potential drug for the treatment of septic AKI.
Supporting information
S1 Fig. TNF-α level after CLP procedure. TNF-α level increased up to 8 h after the CLP pro-
cedure and then decreased over time. † P� 0.01 vs. 0 h. ‡ P� 0.001 vs. 0 h.
(TIF)
S1 Text. Determination of TNF-α levels after CLP. We investigated changes in TNF-α levels
after CLP. TNF-α concentrations was measured using the rat TNF-α quantikine ELISA kit
(R&D Systems, MN, USA) according to the manufacturer’s instructions.
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